Welcome to HitGen


Enabling Innovative Drug Discovery with Advanced Technologies

  1. Services
  2. Hit Identification

Hit Identification

HitGen provides following approaches for hit identification: DNA-encoded library screening, fragment-based drug discovery, virtual screening, nucleic acid related chemistry and analytical chemistry

HitGen featured DEL screening is a fast-growing and mature technology with many advantages over traditional approaches: 

  • easily accessing trillions of physically existing compounds

  • saving in protein/target consumption

  • short duration in hit identification and validation

  • more cost effective

HitGen has extensive experience in DEL screening by serving many pharma, biotech companies and academic groups. The applications of DEL screening expand from hit identification to hit optimization, protein degrader discovery/optimization and more.

Fragment-based drug discovery is powered by Vernalis (A HitGen Company) with more than 30 years' experience. Vernalis integrates fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets. This requires a deep understanding of the techniques involved and a cautious interpretation of data; an approach grounded on two decades of developing and applying fragment-based lead discovery to challenging targets.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information

XML 地图 | Sitemap 地图